Study of XL820 Given Orally Daily to Subjects With Solid Tumors
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the KIT Inhibitor XL820 Administered Orally Daily to Subjects With Solid Tumors
Sponsor: Exelixis
Listed as NCT00350831, this PHASE1 trial focuses on Cancer and remains completed. Sponsored by Exelixis, it has been updated 5 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Exelixis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • New Brunswick, United States
- • San Antonio, United States